Loading...
Market
Will 23andMe stock price recover to pre-resignation levels by June 30, 2025?
3
Resolution / Starting Odds
Yes • 50%
No • 50%
Stock price data from financial markets
Story
All Seven 23andMe Independent Directors Resign Over CEO's Privatization Plan
Sep 18, 2024, 02:45 PM
All seven independent directors of 23andMe have resigned from the company's board, citing a lack of progress on CEO Anne Wojcicki's proposal to take the company private. The directors expressed disappointment over Wojcicki's failure to provide an actionable proposal after five months of delays. This mass resignation follows an incomplete buyout offer that was rejected in August. Wojcicki has stated she is still committed to the privatization plan and expressed surprise and disappointment at the board's decision. The resignations come amid other challenges for 23andMe, including a recent $30 million settlement for a genetic privacy lawsuit and a significant drop in the company's stock price.
View original story
Similar markets
Above 50% increase • 25%
10% to 50% increase • 25%
0% to 10% increase • 25%
Decrease • 25%
Outperforms NASDAQ • 25%
Performs on par with NASDAQ • 25%
Underperforms NASDAQ • 25%
Delisted from NASDAQ • 25%
Increase by more than 10% • 25%
Increase by less than 10% • 25%
Decrease by less than 10% • 25%
Decrease by more than 10% • 25%
Stock increases by 10% or more • 25%
Stock remains within +/- 10% • 25%
Stock decreases by 10% or more • 25%
Stock remains volatile with no clear trend • 25%
Below $0.50 • 25%
$0.50 - $0.99 • 25%
$1.00 - $1.49 • 25%
$1.50 and above • 25%
Less than $1 • 25%
$1 to $2 • 25%
$2 to $3 • 25%
More than $3 • 25%